Statute Details
- Title: Health Products (Composition of Offences) Regulations 2011
- Act Code: HPA2007-S542-2011
- Type: Subsidiary Legislation (SL)
- Authorising Act: Health Products Act (Cap. 122D), section 72
- Commencement: 3 October 2011
- Current status (as provided): Current version as at 27 March 2026
- Key provisions: Regulation 1 (citation and commencement); Regulation 2 (compoundable offences); Regulation 3 (deletion/amendment of Medical Devices Regulations)
- Compounding mechanism referenced: Section 65 of the Health Products Act (compounding by the Chief Executive or authorised officer)
- Notable amendments in the provided timeline: S 540/2016 (w.e.f. 1 Nov 2016); S 150/2021 (w.e.f. 8 Mar 2021); S 832/2023 (w.e.f. 18 Dec 2023)
What Is This Legislation About?
The Health Products (Composition of Offences) Regulations 2011 (“Composition Regulations”) is a Singapore subsidiary law that identifies which offences under the Health Products Act and its related regulations can be “compounded”. In practical terms, compounding allows certain regulatory breaches to be resolved through the payment of a composition sum, instead of proceeding through the full criminal prosecution process.
The Regulations do not create new offences. Rather, they operate as a procedural and enforcement tool. They specify categories of offences that the Chief Executive of the Health Sciences Authority (HSA), or an officer authorised by the Chief Executive, may compound under section 65 of the Health Products Act. This provides an efficient pathway for enforcement, particularly for matters that are suitable for administrative resolution.
Because the Regulations are updated over time (as shown by amendments in 2016, 2021, and 2023), they also reflect the evolving regulatory landscape for health products—covering active ingredients, cosmetics, medical devices, therapeutic products, clinical trials, retail pharmacy licensing, advertising controls, and newer product categories such as cell, tissue and gene therapy products.
What Are the Key Provisions?
Regulation 1 (Citation and commencement) confirms the legal identity of the instrument and its effective date. It may be cited as the Health Products (Composition of Offences) Regulations 2011 and came into operation on 3 October 2011. For practitioners, this matters when assessing whether compounding was available at the time of an alleged breach.
Regulation 2 (Compoundable offences) is the core of the Regulations. It sets out a detailed list of offences that may be compounded. The operative language provides that the following offences “may be compounded in accordance with section 65 of the Act” by the Chief Executive or an authorised officer. This means compounding is discretionary: the authority may choose to compound, rather than being obliged to do so.
The compoundable offences are grouped into several categories:
(a) Offences under the Health Products Act
Regulation 2(a) lists offences under various sections of the Health Products Act (for example, sections 12(6)(a), 13(6)(a), 14(4), 15(2), 16(2)(a), 17(3), 18(2), 19(2), 20(3), 21(3), 23(3)(a), 35(4), 36(5), 40(3), 41(2), 42(5)(a), 43(3), 44(3)(a), 49(5)(e), (9) or (11), 50, and 66(4)). While the extract does not reproduce the substantive content of those Act provisions, the legal effect is clear: breaches of the specified statutory duties are eligible for compounding.
(aa) Offences under the Health Products (Active Ingredients) Regulations 2023
Regulation 2(aa) (inserted by S 832/2023 w.e.f. 18/12/2023) makes offences under section 47(4) of the Act “relating to a contravention” of the Health Products (Active Ingredients) Regulations 2023 compoundable, except offences relating to contravention of regulations 4 or 5 of those Active Ingredients Regulations. This carve-out is significant: it signals that certain core requirements (regulations 4 and 5) are treated as too serious or too policy-sensitive to be resolved via compounding.
(b) Cosmetic products
Regulation 2(b) makes compoundable offences under regulation 4(3), 10(3), or 11(4)(a) of the Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007. This indicates that specific compliance failures within the ASEAN Cosmetic Directive framework are eligible for compounding.
(c) Medical devices
Regulation 2(c) lists a wide range of compoundable offences under the Health Products (Medical Devices) Regulations 2010, including offences under regulation 13A(3), 31(5), 32(2), 36A(5), 37, 38(3), 39(3), 39A(3), 39B(3), 40(2), 41(3), 43(2), 44(4), 45(3), 46(4), 47(3), 48(6) or (7)(b), and 49(5) or (6)(b). The breadth of this list suggests that many device-related regulatory obligations—such as licensing, registration, or technical compliance—may be handled through compounding, subject to the authority’s discretion.
(d) Therapeutic products
Regulation 2(d) similarly identifies compoundable offences under the Health Products (Therapeutic Products) Regulations 2016, including offences under regulation 21(4), 31(3), 32(4), 33(3), 40, 41(6) or (7)(b), 42(4) or (5)(b), 43(2), 44(3), 45(2), 46(8), 48(7) or 65(3). For practitioners, this is important because therapeutic product compliance is a high-volume area for regulatory enforcement.
(e) Retail pharmacy licensing
Regulation 2(e) makes compoundable an offence under regulation 7(5) of the Health Products (Licensing of Retail Pharmacies) Regulations 2016. This indicates that certain retail pharmacy licensing breaches may be resolved administratively.
(f) Advertising controls
Regulation 2(f) makes compoundable an offence under regulation 15(2) of the Health Products (Advertisement of Therapeutic Products) Regulations 2016, renamed as the Health Products (Advertisement of Specified Health Products) Regulations 2016 from 1 March 2021. The inclusion of the renaming note is practically useful: it helps lawyers track the correct regulatory instrument despite changes in title.
(g) Clinical trials
Regulation 2(g) provides a long list of compoundable offences under the Health Products (Clinical Trials) Regulations 2016, but only in respect of contraventions of specified sub-regulations. The structure is telling: compounding is available for certain clinical trial compliance failures, but not necessarily for all. The extract also includes a limitation phrase: the compoundable offence is “but only in respect of a contravention of regulation …” followed by a detailed list. This drafting approach requires careful cross-checking when advising on whether a particular alleged breach is within the compoundable scope.
(h) Clinical research materials
Regulation 2(h) makes compoundable an offence under regulation 24(1)(a) of the Health Products (Therapeutic Products as Clinical Research Materials) Regulations 2016, renamed as the Health Products (Clinical Research Materials) Regulations 2016 from 1 March 2021.
(i) Oral dental gums
Regulation 2(i) makes compoundable offences under specified regulations of the Health Products (Oral Dental Gums) Regulations 2016.
(j) Cell, tissue and gene therapy products
Regulation 2(j) adds compoundable offences under the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021, including offences under regulation 28(4), 32(3), 33(4), 34(5), 35(3), 44, 45(6) or (7)(b), 46(2), 48(4) or (5)(b), 49(2), 50(3), 51(2) or 56(3). This shows the Regulations’ continuing relevance as new product categories are regulated.
Regulation 3 (Amendment of Health Products (Medical Devices) Regulations 2010) deletes regulation 51 of the Medical Devices Regulations 2010. Although the extract does not state what regulation 51 previously provided, the deletion indicates that the compounding framework or related procedural provisions were restructured. For legal practitioners, the deletion is a reminder to check whether older references to regulation 51 remain in compliance manuals, internal policies, or past correspondence.
How Is This Legislation Structured?
The Composition Regulations are short and structured around three provisions:
Regulation 1 sets out citation and commencement.
Regulation 2 contains the substantive list of compoundable offences, organised by reference to offences under the Health Products Act and under specific Health Products regulations (active ingredients, cosmetics, medical devices, therapeutic products, retail pharmacies, advertising, clinical trials, clinical research materials, oral dental gums, and cell/tissue/gene therapy products).
Regulation 3 performs a targeted amendment by deleting a specific provision in the Medical Devices Regulations 2010.
Who Does This Legislation Apply To?
Although the Regulations do not expressly define “who is liable”, the offences they reference are regulatory offences that typically arise from the conduct of regulated persons and entities under the Health Products regulatory framework. In practice, this includes manufacturers, importers, distributors, retailers, advertisers, clinical trial sponsors/investigators (depending on the underlying regulations), and other persons responsible for compliance with licensing, registration, product standards, labelling/advertising, and clinical trial obligations.
The compounding power is exercised by the Chief Executive of HSA or an authorised officer. Therefore, the Regulations primarily govern the enforcement discretion and resolution pathway available to the regulator, rather than imposing direct compliance duties on their own. However, because the compoundable offences are tied to underlying substantive obligations, the practical compliance impact is significant for regulated businesses and professionals.
Why Is This Legislation Important?
This instrument is important because it directly affects enforcement strategy and case outcomes. For a practitioner, the availability of compounding can change how a matter is handled—potentially reducing time, cost, and reputational harm compared to prosecution. It also provides a structured alternative for resolving certain regulatory breaches where the authority considers compounding appropriate.
At the same time, the Regulations are not a blanket amnesty. The list is carefully drafted, and some offences are explicitly excluded (for example, the carve-out for contraventions of regulations 4 or 5 in the Active Ingredients Regulations 2023). This means lawyers must not assume that any breach within a regulated area is compoundable. Instead, they must map the alleged conduct to the specific offence provisions and sub-regulations listed in Regulation 2.
Finally, the amendments over time (2016, 2021, 2023) show that compounding eligibility evolves with Singapore’s health products regulatory regime. Practitioners advising on compliance programmes, internal escalation protocols, or settlement discussions should ensure they rely on the current version and the latest amendment history, particularly where new product categories or renamed regulations are involved.
Related Legislation
- Health Products Act (Cap. 122D) — in particular section 65 (compounding) and section 72 (making of regulations)
- Health Products (Active Ingredients) Regulations 2023 (G.N. No. S 831/2023)
- Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 (G.N. No. S 683/2007)
- Health Products (Medical Devices) Regulations 2010 (G.N. No. S 436/2010)
- Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016)
- Health Products (Licensing of Retail Pharmacies) Regulations 2016 (G.N. No. S 330/2016)
- Health Products (Advertisement of Therapeutic Products) Regulations 2016 / Health Products (Advertisement of Specified Health Products) Regulations 2016 (G.N. No. S 333/2016)
- Health Products (Clinical Trials) Regulations 2016 (G.N. No. S 331/2016)
- Health Products (Therapeutic Products as Clinical Research Materials) Regulations 2016 / Health Products (Clinical Research Materials) Regulations 2016 (G.N. No. S 332/2016)
- Health Products (Oral Dental Gums) Regulations 2016 (G.N. No. S 539/2016)
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021)
Source Documents
This article provides an overview of the Health Products (Composition of Offences) Regulations 2011 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.